Share price · JNJ
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(49 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | —Small molecule | Migraine | |
| Approved | EGFR x c-METMultispecific antibody | Non-Small Cell Lung Cancer | |
Bosentan(Tracleer) | Approved | Endothelin receptor (ETA/ETB, dual)Small molecule | Hypertension |
Canagliflozin(Invokana) | Approved | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
| Approved | ProteasomeSmall molecule | Multiple Myeloma | |
| Approved | BCMACell therapy | Multiple Myeloma | |
| Approved | CD38Monoclonal antibody | Multiple Myeloma | |
Darunavir(Prezista) | Approved | HIV proteaseSmall molecule | HIV |
Esketamine(Spravato) | Approved | NMDA receptorSmall molecule | Major Depressive Disorder |
Etravirine(Intelence) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
golimumab(Simponi) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseaseRheumatoid Arthritis Ulcerative Colitis |
guselkumab(Tremfya) | Approved | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
| Approved | Dopamine D2 receptor (antagonist)Small molecule | Schizophrenia | |
| Approved | IL-23 receptorPeptide | Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis, Crohn's Disease, Plaque Psoriasis | |
infliximab(Remicade) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.